7/18
06:42 pm
abt
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat [Yahoo! Finance]
Neutral
Report
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat [Yahoo! Finance]
7/18
06:41 pm
abt
Abbott Earnings Beat Forecasts. Why the Stock Is Having Its Worst Day Since 2021. [Yahoo! Finance]
Neutral
Report
Abbott Earnings Beat Forecasts. Why the Stock Is Having Its Worst Day Since 2021. [Yahoo! Finance]
7/18
05:56 pm
abt
Abbott Issues Downbeat Third-Quarter Earnings Outlook; Narrows Full-Year Profit Guidance [Yahoo! Finance]
Low
Report
Abbott Issues Downbeat Third-Quarter Earnings Outlook; Narrows Full-Year Profit Guidance [Yahoo! Finance]
7/18
03:07 pm
abt
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Wells Fargo & Company from $147.00 to $142.00. They now have an "overweight" rating on the stock.
Low
Report
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Wells Fargo & Company from $147.00 to $142.00. They now have an "overweight" rating on the stock.
7/18
12:54 pm
abt
Analysts defend Abbott Labs' stock after Thursday's ‘too punitive' sell-off [CNBC]
Low
Report
Analysts defend Abbott Labs' stock after Thursday's ‘too punitive' sell-off [CNBC]
7/18
11:39 am
abt
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? [Yahoo! Finance]
Low
Report
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year? [Yahoo! Finance]
7/18
11:12 am
abt
Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance [Yahoo! Finance]
Low
Report
Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance [Yahoo! Finance]
7/18
10:48 am
abt
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Raymond James Financial, Inc. from $142.00 to $141.00. They now have an "outperform" rating on the stock.
Low
Report
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at Raymond James Financial, Inc. from $142.00 to $141.00. They now have an "outperform" rating on the stock.
7/18
08:40 am
abt
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at BTIG Research from $148.00 to $145.00. They now have a "buy" rating on the stock.
Low
Report
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at BTIG Research from $148.00 to $145.00. They now have a "buy" rating on the stock.
7/18
08:35 am
abt
Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $145.00 price target on the stock.
Low
Report
Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $145.00 price target on the stock.
7/17
07:14 pm
abt
Abbott Laboratories CEO calls post-earnings stock decline ‘a little bit of an overreaction' [CNBC]
Low
Report
Abbott Laboratories CEO calls post-earnings stock decline ‘a little bit of an overreaction' [CNBC]
7/17
01:50 pm
abt
Why Abbott Laboratories (ABT) Shares Are Plunging Today [Yahoo! Finance]
Low
Report
Why Abbott Laboratories (ABT) Shares Are Plunging Today [Yahoo! Finance]
7/17
11:27 am
abt
Abbott Narrows Its Outlook as COVID-19 Testing Demand Wanes. Its Stock Is Falling. [Yahoo! Finance]
Low
Report
Abbott Narrows Its Outlook as COVID-19 Testing Demand Wanes. Its Stock Is Falling. [Yahoo! Finance]
7/17
11:00 am
abt
Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors [Yahoo! Finance]
Low
Report
Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors [Yahoo! Finance]
7/17
10:19 am
abt
GE Aerospace, Abbott Labs, Elevance: Trending Tickers [Yahoo! Finance Canada]
Low
Report
GE Aerospace, Abbott Labs, Elevance: Trending Tickers [Yahoo! Finance Canada]
7/17
08:56 am
abt
Abbott Laboratories Sheds Nearly 5% On A Rare Guidance Miss [Yahoo! Finance]
Medium
Report
Abbott Laboratories Sheds Nearly 5% On A Rare Guidance Miss [Yahoo! Finance]
7/17
08:05 am
abt
Abbott Laboratories's (NYSE:ABT) Q2 Sales Top Estimates [Yahoo! Finance]
Medium
Report
Abbott Laboratories's (NYSE:ABT) Q2 Sales Top Estimates [Yahoo! Finance]
7/17
07:58 am
abt
Abbott Reports Second-Quarter 2025 Results [Yahoo! Finance]
Medium
Report
Abbott Reports Second-Quarter 2025 Results [Yahoo! Finance]
7/17
07:37 am
abt
Abbott beats quarterly profit estimates on medical devices demand [Yahoo! Finance Canada]
Medium
Report
Abbott beats quarterly profit estimates on medical devices demand [Yahoo! Finance Canada]
7/17
07:30 am
abt
Abbott Reports Second-Quarter 2025 Results
Medium
Report
Abbott Reports Second-Quarter 2025 Results
7/16
08:21 pm
abt
Markets Fight Off Powell Rumor, Close in the Green [Yahoo! Finance]
Medium
Report
Markets Fight Off Powell Rumor, Close in the Green [Yahoo! Finance]
7/16
08:34 am
abt
PolyActiva Expands Executive Team to Drive Transformational Growth and Advance Late-Stage Clinical Development in the U.S. [Yahoo! Finance]
Low
Report
PolyActiva Expands Executive Team to Drive Transformational Growth and Advance Late-Stage Clinical Development in the U.S. [Yahoo! Finance]
7/16
08:24 am
abt
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Mizuho from $130.00 to $140.00. They now have a "neutral" rating on the stock.
Low
Report
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Mizuho from $130.00 to $140.00. They now have a "neutral" rating on the stock.
7/15
11:27 am
abt
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Royal Bank Of Canada from $145.00 to $147.00. They now have an "outperform" rating on the stock.
Low
Report
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Royal Bank Of Canada from $145.00 to $147.00. They now have an "outperform" rating on the stock.
7/15
09:10 am
abt
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Morgan Stanley from $127.00 to $137.00. They now have an "equal weight" rating on the stock.
Low
Report
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Morgan Stanley from $127.00 to $137.00. They now have an "equal weight" rating on the stock.